Dr. Bridget A. Martell M.D. serves as Acting Chief Medical Officer of the Company. Dr. Martell has served as our Acting Chief Medical Officer since February 2020, and was previously our Vice President, Clinical Development since April 2018. From October 2017 to April 2018, Dr. Martell worked as an independent consultant to Kura as founder and managing director of BAM Consultants, LLC, a privately-held clinical development and medical affairs consultative services firm. From June 2015 to September 2017, she served as Senior Vice President, New Product Development at Juniper Pharmaceuticals, a publicly-held specialty pharmaceuticals company. Prior to that time, she held leadership roles of increasing responsibility at Pfizer, Inc., a publicly-held biopharmaceutical company and Purdue Pharma L.P., a privately-held pharmaceutical company. Dr. Martell earned her B.S. in microbiology from Cornell University, her M.A. in molecular immunology from Boston University and her M.D. from the Chicago Medical School. She completed her internship and residency in internal medicine and was an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University. Dr. Martell is board certified in both internal and addiction medicine.
Bridget Martell is 54, he's been the Acting Chief Medical Officer of Kura Oncology Inc since 2020. There are 6 older and 13 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
Bridget's mailing address filed with the SEC is C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Kura Oncology Inc have traded over 16,903,587$ worth of Kura Oncology Inc stock and bought 50,000 units worth 575,000$ . The most active insiders traders include Faheem Hasnain、Troy Edward Wilson、Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of 626,260$. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth 57,922$.
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
Kura Oncology Inc executives and other stock owners filed with the SEC include: